• FDA 2022 DDI Evidence: Oteseconazole in Context

  2026-09-04

  This reference study integrates in vitro, mechanistic modeling, clinical pharmacokinetic, and regulatory data to characterize enzyme- and transporter-mediated drug interactions among 22 FDA-approved small-molecule drugs from 2022. Its analysis places Oteseconazole (VT-1161) among drugs with P-gp and/or BCRP inhibition findings while showing why clinical exposure changes, therapeutic index, and labeling context must be interpreted together.

• Mdivi-1 Workflows for DRP1 and Mitochondrial Fission

  2026-09-03

  Mdivi-1 is a cell-permeable selective DRP1 inhibitor for connecting mitochondrial fission with apoptosis, vascular remodeling, and neuroprotection. This practical guide translates the SP1/ADAM10/DRP1 findings in hypoxia pulmonary hypertension into controlled conditioned-medium experiments, imaging workflows, and troubleshooting strategies.

• Talabostat mesylate: DPP4/FAP Workflows

  2026-09-03

  Talabostat mesylate, also called PT-100, supports practical studies of DPP4/FAP biology, tumor microenvironment modulation, cytokine signaling, and hematopoiesis. This guide connects target verification and cell-based workflows with the newer DPP9-linked inflammasome findings while clearly separating established evidence from exploratory assay design.

• A40926 Production: New Genetic Tools

  2026-09-02

  Yushchuk et al. developed promoter-probe and regulatory-engineering tools for the recalcitrant actinomycete Nonomuraea gerenzanensis, enabling systematic control of A40926 glycopeptide antibiotic biosynthesis. Their results show that overexpressing pathway-specific positive regulators can improve production and provide a practical, knowledge-based strategy for strain improvement.

• Talabostat mesylate: FAP/DPP4 Research Workflows

  2026-09-02

  Talabostat mesylate (PT-100) gives researchers a practical way to connect FAP/DPP4 catalytic activity with immune, stromal, and hematopoietic readouts. This guide distinguishes enzyme inhibition from FAP-activated cytotoxic prodrug strategies and provides assay setup, optimization, and troubleshooting advice.

• Resiniferatoxin and TRPV1-Positive Afferent Silencing

  2026-09-01

  Szallasi’s 2023 review presents Resiniferatoxin (RTX) as an ultra-potent TRPV1 agonist that converts receptor activation into selective, durable silencing of TRPV1-positive sensory afferents. The review connects molecular pharmacology with preclinical, veterinary, and clinical evidence in osteoarthritis, neurogenic bladder dysfunction, cancer pain, and neurogenic inflammation.

• Smoothened Signaling in Honeybee Olfaction

  2026-09-01

  Guo et al. identify and functionally examine Smoothened in Apis mellifera, linking antennal Smo activity with olfactory receptor expression, electrophysiological responses, and odor-guided behavior. The study provides a receptor-proximal framework for investigating Hedgehog signaling in insect sensory biology while clarifying the limits of transferring these findings to vertebrate regenerative models.

• Mitoxantrone BA2039: Reliable Cell Assay Design

  2026-08-31

  Learn how Mitoxantrone (SKU BA2039) can support controlled viability, proliferation, cytotoxicity, and transporter-resistance experiments. This scenario-driven guide covers mechanism, DMSO formulation, protocol optimization, ABCG2 interpretation, and practical product selection.

• Anagliptin (SK-0403) Vascular Research Workflows

  2026-08-30

  Anagliptin (SK-0403) supports two complementary research tracks: biochemical DPP-4 inhibition studies and ex vivo vascular pharmacology. This workflow translates evidence for Kv channel modulation and SERCA pump regulation into practical assay design, controls, and troubleshooting decisions.

• LDN-193189: A Cross-Model Assay Framework

  2026-08-29

  LDN-193189 is an ALK inhibitor for dissecting BMP receptor signaling, epithelial barrier biology, and heterotopic ossification research. This article adds a distinct assay-design perspective by connecting pathway pharmacology with lessons from a scalable human sensory-neuron model of HSV-1 latency—without overstating cross-domain evidence.

• TCAIM, OGDH, and Mitochondrial Metabolic Control

  2026-08-29

  Wang et al. identify TCAIM as a mitochondrial DNAJC co-chaperone that specifically binds native OGDH and promotes its reduction through HSPA9 and LONP1. The study establishes a post-translational mechanism linking mitochondrial proteostasis to OGDH complex activity, carbohydrate catabolism, and broader metabolic regulation in cells and mice.

• Neuromedin S (rat): Practical Protocol Guide

  2026-08-28

  Neuromedin S (rat), SKU B5466, provides a defined endogenous peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling in rat-relevant systems. It is intended for research assay development and pathway studies, not for diagnostic, therapeutic, or medical use, and assay potency must be established experimentally because no directly matched paper evidence is supplied.

• Trelagliptin Succinate and Adipocyte Insulin Resistance

  2026-08-28

  The reference study shows that trelagliptin succinate improves insulin resistance in differentiated 3T3-L1 adipocytes by strengthening IRS-1/AKT signaling, promoting GLUT4 membrane localization, and increasing glucose uptake. It also links treatment with lower free fatty acid and resistin secretion, providing a cellular mechanism that extends beyond the compound’s established incretin-based glucose-lowering activity.

• Trelagliptin succinate: Applied Research Workflows

  2026-08-27

  Translate selective DPP-4 enzyme inhibition into reproducible workflows for glucose, adipocyte, cartilage, bone, and diabetes-associated cognitive research. This guide combines practical dosing, solution handling, stability testing, and the validated HPLC strategy reported for SYR-472 succinate.

• Talabostat mesylate: Cancer Assay Workflows

  2026-08-27

  Talabostat mesylate, also known as PT-100, supports parallel investigation of DPP4/FAP biology, tumor–stroma signaling, and immune readouts. This practical guide separates validated product applications from exploratory NLRP1 experiments inspired by recent inflammasome research.

456 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page